Research Article
Metastatin as a Marker for Hyperandrogenemia in Iraqi Women with Polycystic Ovary Syndrome
Table 1
Comparison between control and PCOS women.
| | Parameters | Control | PCOS | value |
| | Number | 44 | 43 | — | | Age (years), mean ± SD | | | 0.162 | | Parity, median (IQR) | 1 (0.25–2.0) | 2 (1–3) | 0.120 | | Kisspeptin (ng/L), median (IQR) | 235.3 (220.6–258.4) | 322.4 (254.6–377.1) | <0.001 | | BMI, n (%) | | | | | <25 kg/m2 | 21 (47.7%) | 23 (53.5%) | 0.591 | | ≥25 kg/m2 | 23 (52.3%) | 20 (46.5%) | | Hirsutism, n (%) | 0 (0%) | 43 (100%) | <0.001 | | Acne, n (%) | 18 (40.9%) | 27 (62.8%) | 0.041 | | Elevated LH, n (%) | 14 (31.8%) | 27 (62.8%) | 0.004 | | FSH, n (%) | | | | | Normal | 31 (70.5%) | 28 (65.1%) | 0.700 | | Decreased | 9 (20.5%) | 12 (27.9%) | | Elevated | 4 (9.1%) | 3 (7%) | | Increased TSH, n (%) | 11 (25%) | 13 (30.2%) | 0.585 | | Increased PRL, n (%) | 20 (45.5%) | 15 (34.9%) | 0.315 | | SHBG, n (%) | | | | | Normal | 31 (70.5%) | 29 (67.4%) | 0.952 | | Decreased | 11 (25%) | 12 (27.9%) | | Elevated | 2 (4.5%) | 2 (4.7%) | | Increased testosterone, n (%) | 18 (40.9%) | 28 (65.1%) | 0.024 | | DHEAS, n (%) | | | | | Normal | 31 (70.5%) | 30 (69.8%) | 0.923 | | Decreased | 8 (18.2%) | 7 (16.3%) | | Elevated | 5 (11.4%) | 6 (14%) | | Glycemic status, n (%) | | | | | Normal | 25 (56.8%) | 21 (48.8%) | 0.695 | | Decreased | 9 (20.5%) | 9 (20.9%) | | Elevated | 10 (22.7%) | 13 (30.2%) | | Impaired lipid profile | 14 (31.8%) | 16 (37.2%) | 0.597 |
|
|
SD: standard deviation, n: number, IQR: interquartile range (25th–57th percentile), PRL: prolactin, SHBG: sex hormone-binding globulin, T: testosterone, DHEAS: dehydroepiandrosterone sulfate, and FPG: fasting blood glucose.
|
